PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology

Experimental oncology commonly uses cells as oncological models, providing a framework for the testing of drugs, and investigation of cytotoxicity, mutagenesis and carcinogenesis. Investigations into poly-ADP-ribose polymerase 1 (PARP1) inhibition have become ever more relevant due to its approval a...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2021-05, Vol.41 (5), p.2397-2402
Main Authors: Machado, Caio Bezerra, DA Silva, Emerson Lucena, Dias Nogueira, Beatriz Maria, DE Moraes Filho, Manoel Odorico, Montenegro, Raquel Carvalho, DE Moraes, Maria Elisabete Amaral, Moreira-Nunes, Caroline Aquino
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Adenosine diphosphate
Biotechnology
BRCA1 protein
Burkitt's lymphoma
Carcinogenesis
Carcinogens
Cell culture
Chronic myeloid leukemia
Cytotoxicity
Deoxyribonucleic acid
Disorders
DNA
DNA repair
Gene expression
Hematological diseases
Hematology
Leukemia
Lymphatic leukemia
Lymphoma
Mutagenesis
Mutation
Myeloid leukemia
Oncology
Poly(ADP-ribose) polymerase
Polymerase chain reaction
Ribose
Toxicity
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Experimental oncology commonly uses cells as oncological models, providing a framework for the testing of drugs, and investigation of cytotoxicity, mutagenesis and carcinogenesis. Investigations into poly-ADP-ribose polymerase 1 (PARP1) inhibition have become ever more relevant due to its approval as a therapeutic option for tumors with BRCA1/2 DNA repair-associated mutation and the seemingly high PARP expression levels in some tumor subtypes. In this study, we aimed to determine PARP1 gene expression of different hematological cancer-derived cell lineages and compare them to that of normal cell lines. PARP1 gene expression in seven different neoplastic lineages, representing three different hematological disorders (chronic myeloid leukemia, Burkitt lymphoma and acute lymphoblastic leukemia), was quantified by quantitative real-time polymerase chain reaction. All hematological malignant lineages in this study overexpressed PARP1 when compared to the normal cell line MRC-5, with Burkitt's lymphoma cells having the highest expression values (fold change: 93). Overexpression of PARP1 in hematological malignant lineages is a finding of crucial importance to future studies exploring possible cellular oncogenic pathways and supports investigations into the effectiveness of PARP1 inhibitors against hematological disorders.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.15014